FDA support advances biomarker for earlier, more precise Parkinson's clinical trials
The Critical Path Institute (C-Path) has published "Regulatory endorsement for the application of alpha-synuclein seed amplification assay (αSyn-SAA) as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies" in the Journal of Parkinson's Disease, marking a significant milestone for its Critical Path for Parkinson's consortium. The findings detail scientific,…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
